LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody–Induced Tumor Cell Killing by Effector CD8+ T CellsAeRyon Kim, Xin Yu, Chia-Jung Han et al.|The Journal of Immunology|2019Cited by 45
<i>In vitro</i> models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of <scp>CRISPR</scp> perturbationsElysia C. Saputra, Aleksandra Olow, Shamsudheen Karuthedath Vellarikkal et al.|Molecular Oncology|2025Cited by 1
Supplementary Figure S5 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1Suchitra Natarajan, Xin Yu, Khoa Nguyen et al.|Unknown|2026Cited by 0
Supplementary Figure S2 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1Suchitra Natarajan, Xin Yu, Khoa Nguyen et al.|Unknown|2026Cited by 0
Figure S1 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1Suchitra Natarajan, Xin Yu, Khoa Nguyen et al.|Unknown|2026Cited by 0